

1647



SEP 04 2002 Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Applicati n Number	09/736,968	
	Filing Date	December 13, 2000	
	First Named Inventor	Lu, Peter S.	
	Group Art Unit	1647	
	Examiner Name	Bridget E. Bunner	
Total Number of Pages in This Submission	1	Attorney Docket Number	020054-000611US

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

COPY OF PAPERS  
ORIGINALY FILED

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm and Individual name	Townsend and Townsend and Crew LLP Brigitte A. Hajos Reg. No. 50,971
Signature	
Date	August 29, 2002

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: August 29, 2002	
Typed or printed name	Kathy Johnston
Signature	
Date	August 29, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3247017 v1



LU et al.  
Application No.: 09/736,968  
Page 1

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900

#14  
*[Signature]*  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LU et al.

Application No.: 09/736,968

Filed: December 13, 2000

For: **CLASP-7 TRANSMEMBRANE  
PROTEIN**

Examiner: Bridget E. Bunner

Art Unit: 1647

RESPONSE TO RESTRICTION  
REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Responsive to the Office Action mailed on July 30, 2002, Applicants make the following election.

REMARKS

Claims 1-37 are pending in the application. The Action restricts the invention into 12 groups as follows:

Group A: claims 1-4, 6-15, and 30, drawn to an isolated CLASP-7 polynucleotide, an expression vector, a host cell system, and a method of producing a CLASP-7 polypeptide, classified in class 536, subclass 23.1.

Group B: claims 5, 16-22, and 30, drawn to an isolated CLASP-7 polypeptide, classified in class 530, subclass 350.

Group C: claims 23-25 and 30, drawn to an isolated antibody that specifically binds a polypeptide and a hybridoma capable of secreting an antibody, classified in class 530, subclass 387.1.

Group D: claim 26, drawn to a method of identifying a compound or agent that binds a CLASP-7 polypeptide comprising contacting a CLASP-7 polypeptide with the compounds and detecting the presence of a complex, classified in class 435, subclass 4, for example.

Group E: claim 27, drawn to a method of detecting a CLASP-7 polypeptide comprising contacting the sample with an antibody and determining whether a complex has been formed, classified in class 435, subclass 7.1.

Group F: claim 28, drawn to a method of detecting a CLASP-7 polypeptide [*sic*, polynucleotide] in a sample comprising contacting the sample with a polynucleotide and determining whether a hybridization complex has been formed, classified in class 435, subclass 6.

Group G: claim 29, drawn to a method of detecting a CLASP-7 nucleotide [*sic*, polynucleotide] in a sample comprising using a polynucleotide in an amplification process and determining whether a specific amplification product has been formed, classified in class 435, subclass 6.

Group H: claims 31-33, drawn to a method of inhibiting an immune response in a subject comprising interfering with the expression of a CLASP-7 gene, interfering with the ability of a CLASP-7 protein to bind another cell, and interfering with the ability of a CLASP-7 protein to bind another protein, classified in class 435, subclass 4.

Group I: claim 34, drawn to a method of inhibiting an immune response in a subject comprising administering to the subject a therapeutically effective amount of an antibody which specifically binds a polypeptide, classified in class 424, subclass 139.1.

Group J: claims 35-37, drawn to a method of preventing or treating a CLASP-7 mediated autoimmune disease comprising administering to a subject in need thereof a therapeutically effective amount of a polynucleotide, classified in class 514, subclass 44.

Group K: claims 35-37, drawn to a method of preventing or treating a CLASP-7 mediated autoimmune disease comprising administering to a subject in need

thereof a therapeutically effective amount of a polypeptide, classified in class 512, subclass 2.

Group L: claims 35-37, drawn to a method of preventing or treating a CLASP-7 mediated autoimmune disease comprising administering to a subject in need thereof a therapeutically effective amount of an antibody, classified in class 424, subclass 130.1.

In compliance with the requirement, Applicants elect to prosecute the invention of Group A, claims 1-4, 6-15 and 30. This election is made with traverse.

Applicants respectfully request redefinition of the groups in the interest of administrative efficiency and consistent with art recognized classifications. In particular, Applicants request the following: Combination of Groups A, F and G, drawn to polynucleotides (including an expression vector, a host cell system, and a method of producing a polypeptide); a method of detecting a polynucleotide in a sample by contacting the sample with a polynucleotide to determine whether a hybridization complex has been formed; and a method of detecting a polynucleotide by using a polynucleotide in an amplification process; respectively, into one group. The suggested combination is believed to be more consistent with accepted use and Applicants respectfully request adaptation. Specifically, CLASP-7 polynucleotide sequences and methods of detecting CLASP-7 polynucleotide sequences can be searched together without placing an undue search burden on the Examiner. In fact, MPEP 808.02 states the following: "Where, however, the classification is the same and the field of search is the same and there is no clear indication of separate future classification and field of search, no reasons exist for dividing among related inventions."<sup>1</sup> Thus, Applicants would greatly appreciate if the Examiner would reconsider the restriction requirement and examine Groups A, F and G together.


Applicants also indicate that claim 28 erroneously recites "a method of detecting a CLASP-7 *polypeptide* in a sample" which reflects an unintentional error. Instead, the claim should read "a method of detecting a CLASP-7 *polynucleotide* in a

sample". No new matter is introduced by this correction. Further, Applicants indicate that claim 29 erroneously recites "detecting a CLASP-7 *nucleotide*" which also reflects an unintentional error. Instead, the claim should refer to "detecting a CLASP-7 *polynucleotide*". No new matter is introduced by this correction.

### CONCLUSION

In summary, Applicants elect Group A in compliance with the requirement. The election is made with traverse. Applicants respectfully request redefinition of the groups such as the combination of Groups A, F and G into one group.

Respectfully submitted,



Brigitte A. Hajos  
Reg. No. 50,971

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
BAH  
PA 3246351 v1

---

<sup>1</sup> MPEP 808.02 Related Inventions; (C) A different Field of search